Board of Directors
Chairman of the Board
Mr. Conrad became the Chairman of the Board of Matinas BioPharma in 2012. He also serves as a Director on the Board of Celldex and as an Advisor to the Seaver Autism Center at Mount Sinai Hospital. Mr. Conrad was the former President of Roche Pharmaceuticals in the United States from 1982 until his retirement in 1993. Since then he has served on the boards of Pharmasset (Chairman), Savient, Dura, UroCor, GenVec (Chairman), Sicor, Bone Care International (Chairman), Sapphire Therapeutics (Chairman), the medical advisory board of Henry Schein, and he was a Director and Co-Founder of Reliant Pharmaceuticals. He received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary Doctorate in Humane Letters from Long Island University.
Chief Executive Officer
Mr. Rongen is a Co-Founder of Matinas BioPharma and the Chief Executive Officer. He is also the Founder and Chairman of Essential Fatty Acid Therapeutics, a biotech company focused on the development of innovative fatty acid derivatives. Prior to Matinas BioPharma, Mr. Rongen was Executive Vice President North American Operations for EPAX/Trygg Pharma and Vice President of Life Cycle Management and Intellectual Property at Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. While at Reliant, Mr. Rongen held various earlier positions, including head of the Omacor®/Lovaza® launch team, Executive Director of Marketing for Lescol® and Executive Director of Business Development. Before Reliant, Mr. Rongen was Global Product Director for Humira® at BASF Pharmaceuticals, later acquired by Abbott. He was also a consultant at The Wilkerson Group in New York and with Arthur D. Little in Amsterdam. Mr. Rongen earned an MBA from Kellogg GSM at Northwestern University, and a graduate degree in Molecular Sciences from Wageningen University in the Netherlands.
Mr. Ferrari became a Director of Matinas BioPharma in 2012. He is the founder and CEO of Murami Pharma, a biopharmaceutical development stage company focusing on small-peptide therapeutics. Prior to Murami Pharma, Mr. Ferrari was the CEO of Bioseutica, a multinational holding company comprising KD-Pharma, a leading manufacturer of omega-3-concentrates, and the leading lysozyme manufacturers Fordras and Neova Technologies, amongst others. Over the last 17 years, Mr. Ferrari was founder, common shareholder and senior executive of several multinational companies operating in the pharmaceutical, food and ingredients industries. Besides Bioseutica, these companies include Prospa B.V., a multinational holding company in the pharmaceutical industry, and Societá Prodotti Antibiotici, the Italian pharmaceutical company that developed the first omega-3-based medication. Mr. Ferrari has served on several boards, including Ikonisys, The Fisher Center for the Performing Arts, and St. Simeon, a private family fund. He has 25 years of experience in investing in diverse industries, including real estate, pharmaceuticals, and media and entertainment. Mr. Ferrari earned his degree in International Business Administration from the University of San Francisco.
James S. Scibetta
Mr. Scibetta became a Director of Matinas BioPharma in November 2013. He is currently CEO of Maverick Therapeutics, a development stage immune-oncology company. Prior to Maverick, he was President at Pacira Pharmaceuticals (Nasdaq: PCRX), where he oversaw global R&D, manufacturing and capacity expansion activities, as well as commercial and medical support activities. He joined Pacira as chief financial officer in 2008 and led the company's 2011 IPO and subsequent debt and equity financings. Prior to that, Mr. Scibetta was an executive with Bioenvision Inc. (Nasdaq: BIVN) a commercial stage oncology company acquired by Genzyme, and Merrimack Pharmaceuticals, an oncology-focused systems biology company. Earlier in his career he spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies. He serves as a Board director and chairman of the audit committee of MonoSol Rx. Mr. Scibetta received his Bachelor of Science in Physics from Wake Forest University and an MBA from the University of Michigan.
Adam K. Stern
Mr. Stern has been Head of Private Equity Banking at Aegis Capital Corp. and CEO of SternAegis Ventures since 2012. Prior to Aegis, from 1997 to November 2012, he was with Spencer Trask Ventures, Inc., most recently as a Senior Managing Director, where he managed the structured finance group focusing primarily on the technology and life science sectors. Mr. Stern held increasingly responsible positions from 1989 to 1997 with Josephthal & Co., Inc., members of the New York Stock Exchange, where he served as Senior Vice President and Managing Director of Private Equity Marketing. He has been a FINRA licensed securities broker since 1987 and a General Securities Principal since 1991. Mr. Stern currently serves as a Director of Dance Biopharm, Inc. and is a former Director of InVivo Therapeutics Holdings Corp. (OTCQB: NVIV), Organovo Holdings, Inc. (NYSE MKT: ONVO) and PROLOR Biotech (formerly NYSE MKT: PBTH). Mr. Stern holds a Bachelor of Arts degree with honors from The University of South Florida in Tampa.
Eric J. Ende, M.B.A, M.D.
Since 2009, Dr. Ende has served as president of Ende BioMedical Consulting Group, a privately-held consulting company which is focused on helping life sciences companies raise capital, identify licensing partners, and optimize corporate structure as well as analyzing both private and public investment opportunities for clients within the life sciences industry. Dr. Ende serves as Co-Founder, Chief Executive and Chief Financial Officer of WellFit Holdings, LLC, a private company focused on developing fitness technologies. In addition, Dr. Ende consulted with Icahn Enterprises in their efforts to appoint board members at Forest Labs, Genzyme, Biogen IDEC, and Amylin. Dr. Ende served on the board of directors and as a member of the audit and risk management committee of Genzyme Corp. (NASDAQ: GENZ) from 2010 until it was acquired by Sanofi (NSYE: SNY) in 2011. Dr. Ende is currently serving on the Technology Transfer Committee of Mount Sinai Innovation Partners and served as the Chairman of the Unsecured Creditor's Committee overseeing the bankruptcy of Egenix, Inc. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 through 2002, Dr. Ende was the senior biotechnology analyst at Banc of America Securities and, from 1997 to 2000, he was a biotechnology analyst at Lehman Brothers. Dr. Ende received an MBA in Finance and Accounting from NYU - Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.